Supercell Acquires Exclusive Licensing from Japanese Immunotherapy Leader for Advanced NK Cell Treatment Technology

Supercell Biotechnology Corporation commemorates the first anniversary of rebranding from previously-called SinoCell Technologies, due to the company’s capital increase by RMT Holding Group. Demonstrating the strategic move at the Healthcare+ Expo Taiwan, their theme “Hope Begins from Now”, encapsulates their global expansion and transformation in healthcare.

Supercell, through partnerships in regenerative medicine, has secured an exclusive license for a Japanese-developed natural killer (NK) cell culture technique. The technique, pivotal in cancer cell elimination and immune system enhancement, will be showcased at the expo, highlighting their latest experimental advancements[1].

The majority of NK cells administered on day 14 are CD56brightCD16NK cells, which primarily enhance immune function but show reduced expression of the CD16 membrane protein, crucial for tumor cell destruction. Dr. Hiroshi Terunuma’s methodology indicates that by day 21, CD56brightCD16+NK cells become the dominant cell type. These cells demonstrate increased expression of both CD56 and CD16 membrane proteins, enabling both cytotoxic and immunomodulatory effects. The results showed both qualitative and quantitative enhancements, as evidenced by the presence of more than 60 x 108 NK cells, a purity level greater than 80%, and an amplification rate exceeding 1,500-fold.

Dr. Hiroshi Terunuma, a distinguished international authority in cancer treatment based in Japan and a long-standing partner of Supercell, has successfully administered NK cell therapy in over 40,000 cases. In a clinical study, 63 patients diagnosed with terminal malignant pancreatic cancer received conventional cancer therapy supplemented by NK cell infusion. Results showed a significant improvement in survival rates, with 41 patients doubling their expected lifespan from 6 to 13 months[2]. Moreover, a British patient with terminal colon cancer achieved a complete remission, showcasing the effectiveness and progressive potential of NK cell therapy.[3]

If adopted as a standard practice in future healthcare, this approach could enhance cellular immunity, potentially leading to increased resilience in the face of a progressively complex disease environment.

Sean Ishihara, Chairman of RMT Group, parent company of Supercell Biotechnology Corporation, emphasizes, “medical care is a universal right.” Unlike typical biotech companies focused on going public, Supercell prioritizes researching and developing safe, effective biotech applications. The company actively collaborates with international experts to realize this mission. Through these partnerships, Supercell aims to deliver top-quality solutions worldwide.

[1] Terunuma, H. Autologous Immune Enhancement Therapy for Cancer—Our experience since 2004. J. Stem Cells Regen. Med. 2012, 8, 205–206.

[2] Terunuma H, Deng X, Nishino N, Watanabe K. NK cell-based autologous immune enhancement therapy (AIET) for cancer. J Stem Cells Regen Med. 2013 Apr 30;9(1):9-13. doi: 10.46582/jsrm.0901003. PMID: 24693203; PMCID: PMC3908307.

[3] (Colon cancer patient who turned away from NHS ‘disease free’ 6 years after being told he had months to live, By Paul Gallagher, September 10, 2022 6:00 am (Updated at September 13, 2022 11:05 am))

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy